Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma.

Lassman AB, Aldape KD, Ansell PJ, Bain E, Curran WJ, Eoli M, French PJ, Kinoshita M, Looman J, Mehta M, Muragaki Y, Narita Y, Ocampo C, Roberts-Rapp L, Song M, Vogelbaum MA, Walenkamp AME, Wang TJC, Zhang P, van den Bent MJ.

J Neurooncol. 2019 Jul 4. doi: 10.1007/s11060-019-03222-y. [Epub ahead of print]

PMID:
31273577
2.

Barriers to Accrual and Enrollment in Brain Tumor Trials.

Lee EQ, Chukwueke UN, Hervey-Jumper SL, de Groot JF, Leone JP, Armstrong TS, Chang SM, Arons D, Oliver K, Verble K, Musella A, Willmarth N, Alexander BM, Bates A, Doherty L, Galanis E, Gaffey S, Halkin T, Friday BE, Fouladi M, Lin NU, Macdonald D, Mehta MP, Penas-Prado M, Vogelbaum MA, Sahebjam S, Sandak D, van den Bent M, Weller M, Reardon DA, Wen PY.

Neuro Oncol. 2019 Jun 7. pii: noz104. doi: 10.1093/neuonc/noz104. [Epub ahead of print]

PMID:
31175826
3.

Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO/SNO Joint Endorsement Summary of College of Neurologic Surgeons Guidelines.

Chang SM, Messersmith H, Vogelbaum MA.

J Oncol Pract. 2019 Jul;15(7):395-397. doi: 10.1200/JOP.19.00058. Epub 2019 May 24. No abstract available.

PMID:
31125284
4.

Nodular Leptomeningeal Disease After Surgery for a Brain Metastasis - Should We Be Concerned?

Vogelbaum MA, Yu HM.

Neuro Oncol. 2019 May 3. pii: noz081. doi: 10.1093/neuonc/noz081. [Epub ahead of print] No abstract available.

PMID:
31051044
5.

Risk Factors for Progression Among Low-Grade Gliomas After Gross Total Resection and Initial Observation in the Molecular Era.

Tom MC, Varra V, Leyrer CM, Park DY, Chao ST, Yu JS, Suh JH, Reddy CA, Balagamwala EH, Broughman JR, Kotagal KA, Vogelbaum MA, Barnett GH, Ahluwalia MS, Peereboom DM, Prayson RA, Stevens GHJ, Murphy ES.

Int J Radiat Oncol Biol Phys. 2019 Apr 22. pii: S0360-3016(19)30631-5. doi: 10.1016/j.ijrobp.2019.04.010. [Epub ahead of print]

PMID:
31022510
6.

Chromatin landscapes reveal developmentally encoded transcriptional states that define human glioblastoma.

Mack SC, Singh I, Wang X, Hirsch R, Wu Q, Villagomez R, Bernatchez JA, Zhu Z, Gimple RC, Kim LJY, Morton A, Lai S, Qiu Z, Prager BC, Bertrand KC, Mah C, Zhou W, Lee C, Barnett GH, Vogelbaum MA, Sloan AE, Chavez L, Bao S, Scacheri PC, Siqueira-Neto JL, Lin CY, Rich JN.

J Exp Med. 2019 May 6;216(5):1071-1090. doi: 10.1084/jem.20190196. Epub 2019 Apr 4.

PMID:
30948495
7.

Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines.

Chang SM, Messersmith H, Ahluwalia M, Andrews D, Brastianos PK, Gaspar LE, Gatson NN, Jordan JT, Khasraw M, Lassman AB, Maues J, Mrugala M, Raizer J, Schiff D, Stevens G, Sumrall A, Van den Bent M, Vogelbaum MA.

Neuro Oncol. 2019 Mar 18;21(4):424-427. doi: 10.1093/neuonc/noz034.

PMID:
30883663
8.

Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines.

Chang SM, Messersmith H, Ahluwalia M, Andrews D, Brastianos PK, Gaspar LE, Gatson NTN, Jordan JT, Khasraw M, Lassman AB, Maues J, Mrugala M, Raizer J, Schiff D, Stevens G, Sumrall A, van den Bent M, Vogelbaum MA.

J Clin Oncol. 2019 May 1;37(13):1130-1135. doi: 10.1200/JCO.18.02085. Epub 2019 Mar 18.

PMID:
30883246
9.

The Impact of Sequencing PD-1/PD-L1 Inhibitors and Stereotactic Radiosurgery for Patients with Brain Metastasis.

Kotecha R, Kim JM, Miller JA, Juloori A, Chao ST, Murphy ES, Peereboom DM, Mohammadi AM, Barnett GH, Vogelbaum MA, Angelov L, Suh JH, Ahluwalia MS.

Neuro Oncol. 2019 Feb 23. pii: noz046. doi: 10.1093/neuonc/noz046. [Epub ahead of print]

PMID:
30796838
10.

Recent Developments and Future Directions in Adult Lower-Grade Gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus.

Schiff D, van den Bent M, Vogelbaum MA, Wick W, Miller CR, Taphoorn M, Pope W, Brown PD, Platten M, Jalali R, Armstrong T, Wen PY.

Neuro Oncol. 2019 Feb 8. doi: 10.1093/neuonc/noz033. [Epub ahead of print]

PMID:
30753579
11.

Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.

Parsai S, Miller JA, Juloori A, Chao ST, Kotecha R, Mohammadi AM, Ahluwalia MS, Murphy ES, Barnett GH, Vogelbaum MA, Angelov L, Peereboom DM, Suh JH.

J Neurosurg. 2019 Feb 8:1-9. doi: 10.3171/2018.10.JNS182340. [Epub ahead of print]

PMID:
30738402
12.

Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis.

Kim JM, Miller JA, Kotecha R, Chao ST, Ahluwalia MS, Peereboom DM, Mohammadi AM, Barnett GH, Murphy ES, Vogelbaum MA, Angelov L, Abraham J, Moore H, Budd GT, Suh JH.

Neuro Oncol. 2019 May 6;21(5):659-668. doi: 10.1093/neuonc/noz006.

PMID:
30726965
13.

Combined use of minimal access craniotomy, intraoperative magnetic resonance imaging, and awake functional mapping for the resection of gliomas in 61 patients.

Whiting BB, Lee BS, Mahadev V, Borghei-Razavi H, Ahuja S, Jia X, Mohammadi AM, Barnett GH, Angelov L, Rajan S, Avitsian R, Vogelbaum MA.

J Neurosurg. 2019 Jan 25:1-9. doi: 10.3171/2018.9.JNS181802. [Epub ahead of print]

PMID:
30684941
14.

Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications.

Boire A, Brandsma D, Brastianos PK, Le Rhun E, Ahluwalia M, Junck L, Glantz M, Groves MD, Lee EQ, Lin N, Raizer J, Rudà R, Weller M, Van den Bent MJ, Vogelbaum MA, Chang S, Wen PY, Soffietti R.

Neuro Oncol. 2019 May 6;21(5):571-584. doi: 10.1093/neuonc/noz012.

15.

Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases.

Juloori A, Miller JA, Parsai S, Kotecha R, Ahluwalia MS, Mohammadi AM, Murphy ES, Suh JH, Barnett GH, Yu JS, Vogelbaum MA, Rini B, Garcia J, Stevens GH, Angelov L, Chao ST.

J Neurosurg. 2019 Jan 18:1-9. doi: 10.3171/2018.8.JNS182100. [Epub ahead of print]

PMID:
30660120
16.

Imaging and diagnostic advances for intracranial meningiomas.

Huang RY, Bi WL, Griffith B, Kaufmann TJ, la Fougère C, Schmidt NO, Tonn JC, Vogelbaum MA, Wen PY, Aldape K, Nassiri F, Zadeh G, Dunn IF; International Consortium on Meningiomas .

Neuro Oncol. 2019 Jan 14;21(Supplement_1):i44-i61. doi: 10.1093/neuonc/noy143.

PMID:
30649491
17.

Molecular and translational advances in meningiomas.

Suppiah S, Nassiri F, Bi WL, Dunn IF, Hanemann CO, Horbinski CM, Hashizume R, James CD, Mawrin C, Noushmehr H, Perry A, Sahm F, Sloan A, Von Deimling A, Wen PY, Aldape K, Zadeh G; International Consortium on Meningiomas .

Neuro Oncol. 2019 Jan 14;21(Supplement_1):i4-i17. doi: 10.1093/neuonc/noy178.

PMID:
30649490
18.

Advances in multidisciplinary therapy for meningiomas.

Brastianos PK, Galanis E, Butowski N, Chan JW, Dunn IF, Goldbrunner R, Herold-Mende C, Ippen FM, Mawrin C, McDermott MW, Sloan A, Snyder J, Tabatabai G, Tatagiba M, Tonn JC, Wen PY, Aldape K, Nassiri F, Zadeh G, Jenkinson MD, Raleigh DR; International Consortium on Meningiomas .

Neuro Oncol. 2019 Jan 14;21(Supplement_1):i18-i31. doi: 10.1093/neuonc/noy136.

PMID:
30649489
19.

Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life.

Nassiri F, Price B, Shehab A, Au K, Cusimano MD, Jenkinson MD, Jungk C, Mansouri A, Santarius T, Suppiah S, Teng KX, Toor GS, Zadeh G, Walbert T, Drummond KJ; International Consortium on Meningiomas .

Neuro Oncol. 2019 Jan 14;21(Supplement_1):i32-i43. doi: 10.1093/neuonc/noy152.

PMID:
30649488
20.

Erratum. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539.

Rogers L, Zhang P, Vogelbaum MA, Mehta MP.

J Neurosurg. 2018 Dec 1;129(6):1650. doi: 10.3171/2018.8.JNS161170a. No abstract available.

PMID:
30485244
21.

Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery.

Sharma M, Schroeder JL, Elson P, Meola A, Barnett GH, Vogelbaum MA, Suh JH, Chao ST, Mohammadi AM, Stevens GHJ, Murphy ES, Angelov L.

J Neurosurg. 2018 Oct 1:1-11. doi: 10.3171/2018.4.JNS172909. [Epub ahead of print]

PMID:
30485180
22.

Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis.

Alban TJ, Alvarado AG, Sorensen MD, Bayik D, Volovetz J, Serbinowski E, Mulkearns-Hubert EE, Sinyuk M, Hale JS, Onzi GR, McGraw M, Huang P, Grabowski MM, Wathen CA, Ahluwalia MS, Radivoyevitch T, Kornblum HI, Kristensen BW, Vogelbaum MA, Lathia JD.

JCI Insight. 2018 Nov 2;3(21). pii: 122264. doi: 10.1172/jci.insight.122264.

23.

Supratotal resection in glioma: a systematic review.

de Leeuw CN, Vogelbaum MA.

Neuro Oncol. 2019 Feb 14;21(2):179-188. doi: 10.1093/neuonc/noy166.

PMID:
30321384
24.

Personalized therapeutic delivery in the neurosurgical operating room.

Vogelbaum MA.

Proc Natl Acad Sci U S A. 2018 Sep 4;115(36):8846-8848. doi: 10.1073/pnas.1812559115. Epub 2018 Aug 20. No abstract available.

25.

Targeted Therapies for Brain Tumors: Will They Ever Deliver?

Vogelbaum MA.

Clin Cancer Res. 2018 Aug 15;24(16):3790-3791. doi: 10.1158/1078-0432.CCR-18-0855. Epub 2018 May 24.

PMID:
29798907
26.

Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.

Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM, Blakeley J, Chamberlain MC, Dunbar E, Loong HH, Macdonald DR, Reardon DA, Vogelbaum MA, Yuan Y, Weller M, van den Bent M, Wen PY.

Neuro Oncol. 2018 Jun 18;20(7):897-906. doi: 10.1093/neuonc/noy056.

27.

Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.

Cloughesy TF, Landolfi J, Vogelbaum MA, Ostertag D, Elder JB, Bloomfield S, Carter B, Chen CC, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu P, Piccioni D, Accomando W, Diago OR, Hogan DJ, Gammon D, Kasahara N, Kheoh T, Jolly DJ, Gruber HE, Das A, Walbert T.

Neuro Oncol. 2018 Sep 3;20(10):1383-1392. doi: 10.1093/neuonc/noy075.

PMID:
29762717
28.

First-in-human evaluation of the Cleveland Multiport Catheter for convection-enhanced delivery of topotecan in recurrent high-grade glioma: results of pilot trial 1.

Vogelbaum MA, Brewer C, Barnett GH, Mohammadi AM, Peereboom DM, Ahluwalia MS, Gao S.

J Neurosurg. 2018 Apr 1:1-10. doi: 10.3171/2017.10.JNS171845. [Epub ahead of print]

PMID:
29652233
29.

Population description and clinical response assessment for spinal metastases: part 2 of the SPIne response assessment in Neuro-Oncology (SPINO) group report.

Laufer I, Lo SS, Chang EL, Sheehan J, Guckenberger M, Sohn MJ, Ryu S, Foote M, Muacevic A, Soltys SG, Chao S, Myrehaug S, Gerszten PC, Lis E, Maralani P, Bilsky M, Fisher C, Rhines L, Verlaan JJ, Schiff D, Fehlings MG, Ma L, Chang S, Parulekar WR, Vogelbaum MA, Sahgal A.

Neuro Oncol. 2018 Aug 2;20(9):1215-1224. doi: 10.1093/neuonc/noy047.

PMID:
29590465
30.

Risk Factors for Malignant Transformation of Low-Grade Glioma.

Murphy ES, Leyrer CM, Parsons M, Suh JH, Chao ST, Yu JS, Kotecha R, Jia X, Peereboom DM, Prayson RA, Stevens GHJ, Barnett GH, Vogelbaum MA, Ahluwalia MS.

Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):965-971. doi: 10.1016/j.ijrobp.2017.12.258. Epub 2017 Dec 21.

PMID:
29485076
31.

Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

Alexander BM, Brown PD, Ahluwalia MS, Aoyama H, Baumert BG, Chang SM, Gaspar LE, Kalkanis SN, Macdonald DR, Mehta MP, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Lee EQ, Wen PY; Response Assessment in Neuro-Oncology (RANO) group.

Lancet Oncol. 2018 Jan;19(1):e33-e42. doi: 10.1016/S1470-2045(17)30692-7. Review.

PMID:
29304360
32.

Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539.

Rogers L, Zhang P, Vogelbaum MA, Perry A, Ashby LS, Modi JM, Alleman AM, Galvin J, Brachman D, Jenrette JM, De Groot J, Bovi JA, Werner-Wasik M, Knisely JPS, Mehta MP.

J Neurosurg. 2018 Jul;129(1):35-47. doi: 10.3171/2016.11.JNS161170. Epub 2017 Oct 6. Erratum in: J Neurosurg. 2018 Dec 1;129(6):1650.

33.

Phase I Trial of Radiosurgery Dose Escalation Plus Bevacizumab in Patients With Recurrent/Progressive Glioblastoma.

Abbassy M, Missios S, Barnett GH, Brewer C, Peereboom DM, Ahluwalia M, Neyman G, Chao ST, Suh JH, Vogelbaum MA.

Neurosurgery. 2018 Sep 1;83(3):385-392. doi: 10.1093/neuros/nyx369.

PMID:
28973311
34.

Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm.

Angelov L, Mohammadi AM, Bennett EE, Abbassy M, Elson P, Chao ST, Montgomery JS, Habboub G, Vogelbaum MA, Suh JH, Murphy ES, Ahluwalia MS, Nagel SJ, Barnett GH.

J Neurosurg. 2018 Aug;129(2):366-382. doi: 10.3171/2017.3.JNS162532. Epub 2017 Sep 22.

PMID:
28937324
35.

Primary medical therapy for BRAFV600E-mutant melanoma brain metastases-is this good enough?

Kruser TJ, Vogelbaum MA.

Lancet Oncol. 2017 Sep;18(9):e508. doi: 10.1016/S1470-2045(17)30633-2. No abstract available.

PMID:
28884696
36.

Updated response assessment criteria for high-grade glioma: beyond the MacDonald criteria.

Sharma M, Juthani RG, Vogelbaum MA.

Chin Clin Oncol. 2017 Aug;6(4):37. doi: 10.21037/cco.2017.06.26. Review.

37.

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM.

Lancet. 2017 Oct 7;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8. Erratum in: Lancet. 2017 Oct 7;390(10103):1644.

38.

Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.

Kotecha R, Miller JA, Venur VA, Mohammadi AM, Chao ST, Suh JH, Barnett GH, Murphy ES, Funchain P, Yu JS, Vogelbaum MA, Angelov L, Ahluwalia MS.

J Neurosurg. 2018 Jul;129(1):50-59. doi: 10.3171/2017.1.JNS162797. Epub 2017 Aug 11.

PMID:
28799876
39.

First follow-up radiographic response is one of the predictors of local tumor progression and radiation necrosis after stereotactic radiosurgery for brain metastases.

Sharma M, Jia X, Ahluwalia M, Barnett GH, Vogelbaum MA, Chao ST, Suh JH, Murphy ES, Yu JS, Angelov L, Mohammadi AM.

Cancer Med. 2017 Sep;6(9):2076-2086. doi: 10.1002/cam4.1149. Epub 2017 Aug 4.

40.

Validation of the Disease-Specific GPA for Patients With 1 to 3 Synchronous Brain Metastases in Newly Diagnosed NSCLC.

Woody NM, Greer MD, Reddy CA, Videtic GMM, Chao ST, Murphy ES, Suh JH, Angelov L, Barnett GH, Vogelbaum MA, Stephans KL.

Clin Lung Cancer. 2018 Jan;19(1):e141-e147. doi: 10.1016/j.cllc.2017.06.011. Epub 2017 Jul 6.

PMID:
28739316
41.

Cumulative Intracranial Tumor Volume and Number of Brain Metastasis as Predictors of Developing New Lesions After Stereotactic Radiosurgery for Brain Metastasis.

Sharma M, Jia X, Ahluwalia M, Barnett GH, Vogelbaum MA, Chao ST, Suh JH, Murphy ES, Yu JS, Angelov L, Mohammadi AM.

World Neurosurg. 2017 Oct;106:666-675. doi: 10.1016/j.wneu.2017.07.048. Epub 2017 Jul 19.

PMID:
28735139
42.

Evaluation of Prognostic Factors for Early Mortality After Stereotactic Radiosurgery for Brain Metastases: a Single Institutional Retrospective Review.

Bennett EE, Vogelbaum MA, Barnett GH, Angelov L, Chao S, Murphy E, Yu J, Suh JH, Elson P, Stevens GHJ, Mohammadi AM.

Neurosurgery. 2018 Jul 1;83(1):128-136. doi: 10.1093/neuros/nyx346.

PMID:
28673040
43.

Response Assessment in Neuro-Oncology Clinical Trials.

Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ.

J Clin Oncol. 2017 Jul 20;35(21):2439-2449. doi: 10.1200/JCO.2017.72.7511. Epub 2017 Jun 22. Review.

44.

PET imaging in patients with meningioma-report of the RANO/PET Group.

Galldiks N, Albert NL, Sommerauer M, Grosu AL, Ganswindt U, Law I, Preusser M, Le Rhun E, Vogelbaum MA, Zadeh G, Dhermain F, Weller M, Langen KJ, Tonn JC.

Neuro Oncol. 2017 Nov 29;19(12):1576-1587. doi: 10.1093/neuonc/nox112. Review.

45.

The Prognostic Role of Tumor Volume in the Outcome of Patients with Single Brain Metastasis After Stereotactic Radiosurgery.

Bennett EE, Angelov L, Vogelbaum MA, Barnett GH, Chao ST, Murphy ES, Yu JS, Suh JH, Jia X, Stevens GHJ, Ahluwalia MS, Mohammadi AM.

World Neurosurg. 2017 Aug;104:229-238. doi: 10.1016/j.wneu.2017.04.156. Epub 2017 May 3.

PMID:
28478250
46.

The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.

Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, Cloughesy T, Iwamoto FM, Tonn JC, Vogelbaum MA, Wen PY, van den Bent MJ, Reardon DA.

Neuro Oncol. 2017 May 1;19(5):625-635. doi: 10.1093/neuonc/nox029. Review.

47.

An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.

Gittleman H, Lim D, Kattan MW, Chakravarti A, Gilbert MR, Lassman AB, Lo SS, Machtay M, Sloan AE, Sulman EP, Tian D, Vogelbaum MA, Wang TJC, Penas-Prado M, Youssef E, Blumenthal DT, Zhang P, Mehta MP, Barnholtz-Sloan JS.

Neuro Oncol. 2017 May 1;19(5):669-677. doi: 10.1093/neuonc/now208.

48.

The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies.

Kim JM, Miller JA, Kotecha R, Xiao R, Juloori A, Ward MC, Ahluwalia MS, Mohammadi AM, Peereboom DM, Murphy ES, Suh JH, Barnett GH, Vogelbaum MA, Angelov L, Stevens GH, Chao ST.

J Neurooncol. 2017 Jun;133(2):357-368. doi: 10.1007/s11060-017-2442-8. Epub 2017 Apr 22.

PMID:
28434110
49.

Quality of Life following Stereotactic Radiosurgery for Single and Multiple Brain Metastases.

Miller JA, Kotecha R, Barnett GH, Suh JH, Angelov L, Murphy ES, Vogelbaum MA, Mohammadi A, Chao ST.

Neurosurgery. 2017 Jul 1;81(1):147-155. doi: 10.1093/neuros/nyw166.

PMID:
28327994
50.

Three or More Courses of Stereotactic Radiosurgery for Patients with Multiply Recurrent Brain Metastases.

Kotecha R, Damico N, Miller JA, Suh JH, Murphy ES, Reddy CA, Barnett GH, Vogelbaum MA, Angelov L, Mohammadi AM, Chao ST.

Neurosurgery. 2017 Jun 1;80(6):871-879. doi: 10.1093/neuros/nyw147.

PMID:
28327948

Supplemental Content

Loading ...
Support Center